Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.70 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.70 |
| ▸ | CETP | P11597 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 3/20 | 0.56 |
| ▸ | GMNN | O75496 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.56 |
| ▸ | CCR6 | P51684 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | UBE2N | P61088 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylspingosine SCHEMBL121926 | 0.83 | SPHK2 (1.00) | SPHK2SPHK1CETPMAPTMEN1 | |
| Dimethylspingosine SCHEMBL121927 | 0.83 | SPHK2 (1.00) | SPHK2SPHK1CETPMAPTMEN1 | |
| Dimethylspingosine SCHEMBL5493697 | 0.83 | SPHK2 (1.00) | SPHK2SPHK1CETPMAPTMEN1 | |
| Dimethylspingosine SCHEMBL8258015 | 0.83 | SPHK2 (1.00) | SPHK2SPHK1CETPMAPTMEN1 | |
| SCHEMBL8912325 | 0.81 | SPHK2 (0.74) | SPHK2SPHK1CETPMAPTMEN1 | |
| SCHEMBL21428462 | 0.80 | SPHK2 (0.72) | SPHK2SPHK1CETPMAPTMEN1 | |
| SCHEMBL23925264 | 0.80 | PLA2G4A (0.67) | SPHK2SPHK1CETPALDH1A1 | |
| Dimethylspingosine SCHEMBL19745875 | 0.79 | SPHK2 (0.86) | SPHK2SPHK1CETPMAPTMEN1 | |
| SCHEMBL11895494 | 0.75 | SPHK2 (0.69) | SPHK2SPHK1CETPMAPTMEN1 | |
| SCHEMBL29472484 | 0.74 | SPHK1 (0.49) | SPHK2SPHK1CETPMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2026-05-19 | — | — | US | disclosed |
| US-12357668-B2 | Anticancer activity of Buddleja saligna compositions | UNIVERSITY OF PRETORIA (ZA) | 2025-07-15 | — | — | US | disclosed |
| US-12208125-B2 | Stable dry powders and emulsions containing probiotics | VIRUN, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240099993-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| US-20230047790-A1 | STABLE DRY POWDERS AND EMULSIONS CONTAINING PROBIOTICS | VIRUN, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-113208956-B | Soybean fermentation liquor with anti-photoaging effect and preparation method and application thereof | 华南理工大学 | 2022-12-16 | — | — | CN | disclosed |
| US-11491194-B2 | Stable dry powders and emulsions containing probiotics | VIRUN, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-4003426-A1 | INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH | Thermalin Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220088109-A1 | Anticancer Activity of Buddleja Saligna Compositions | UNIVERSITY OF PRETORIA (ZA) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240099993-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | SPHK2, SPHK1, S1PR2 | SPHK2 1/4885SPHK1 2/4885CETP 80/4885 |
| US-11491194-B2 | Stable dry powders and emulsions containing probiotics | FABP2, FABP6, MUC1 | SPHK2 236/4885SPHK1 528/4885CETP 191/4885 |
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | S1PR2, S1PR3, S1PR1 | SPHK2 4/4885SPHK1 8/4885CETP 90/4885 |
| US-12208125-B2 | Stable dry powders and emulsions containing probiotics | FABP2, FABP6, MUC1 | SPHK2 236/4885SPHK1 528/4885CETP 191/4885 |
| US-20230047790-A1 | STABLE DRY POWDERS AND EMULSIONS CONTAINING PROBIOTICS | FABP2, FABP6, MUC1 | SPHK2 236/4885SPHK1 528/4885CETP 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.